Tysabri
Boston
About Tysabri
Nearly 400,000* Americans are living with multiple sclerosis (MS). Yet, if you asked each one of them to describe their experience with the disease, you'd probably hear 400,000 unique stories. That's because MS affects everyone differently. The only common thread is that MS is a progressive disease that silently advances. While there's no cure for MS, there is good news. Today the medical community has more knowledge about MS and more medications for treating it than ever before. TYSABRI (natalizumab) increases the risk of PML. For adults with relapsing forms of Multiple Sclerosis (MS). TYSABRI (natalizumab) increases the risk of PML. When starting and continuing treatment with TYSABRI, it is important that you discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk. TYSABRI is usually taken by someone who has seen their physical disability worsen or who hasn't seen the results they'd hoped for with another therapy. And, unlike daily or weekly medications, TYSABRI is given every 4 weeks as an infusion.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Website: tysabri.com
- Phone: 800 456 2255
Social Profiles
Canonical: https://fsome.com/organization/tysabri-1309317 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.